Add Formweb to your mobile device
Search results for:
heparin
heparin
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Heparin | SOLUTION, INJECTABLE | 1000 units/mL | |
| Heparin | SOLUTION, INJECTABLE | 5000 units/mL | |
| Heparin | SOLUTION, INJECTABLE | 10000 units/mL | |
| Heparin | SOLUTION, INJECTABLE | 20000 units/mL | |
| Heparin | SOLUTION, INTRAVENOUS | 10 units/mL-NaCl 0.9% | |
| Dextrose-Heparin | SOLUTION, INTRAVENOUS | 50 units/mL-D5% | |
| Dextrose-Heparin | SOLUTION, INTRAVENOUS | 100 units/mL-D5% |
Last updated: Nov. 30, 2021
- High Alert: CAUTION: See High-Alert Medication Policy
- Black Box Warning: Spinal/Epidural Hematomas
Anticoagulant Management: Policy 900.3207
Anticoagluation Management while on ECMO, see protocol 922.5063
Clinical and Dosing Guidelines:
Heparin per pharmacy protocol: See 916.6002 Heparin Protocols
Pediatric Heparin Protocols (for Non-ECMO Patients): See Protocol 912.6006
ECMO Heparin Anticoagulation for Pediatric Patients: See protocol 922.6000
Neuraxial Anesthesia and Anticoagulation: See Guideline 900.5681
Heparin induced thrombocytopenia (HIT) detection and management: See Guideline 916.5002
Activated clotting time (ACT) testing for LEMC only: See Policy 914.4306
For Heparin use with Impella: See 901.6005 Impella Ventricular Support System Protocol
Antithrombotic and Anticoagulant Treatment in Stroke: See 900.5018
Reversal Guidelines:
Reversal of heparin in Adults: See Reversal Guideline 900.5010
Reversal of heparin in Pediatrics: See Reversal Guideline 900.5866